Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
STRO-001 · 1 trial · 8 indications
Incidence of adverse events (AEs) observed across STRO-001 dose levels
Frequency of dose-limiting toxicity and exposure across STRO-001 dose levels
Objective response rates per International Myeloma Working Group (IMWG) criteria for response assessment
Objective response rates per the Lugano classification for response assessment
| Arm | Type | Description |
|---|---|---|
| STRO-001 | EXPERIMENTAL | intravenous |
| Name | Type | Description |
|---|---|---|
| STRO-001 | DRUG | intravenous antibody drug conjugate |
Key Inclusion Criteria: 1. Confirmation of diagnosis 2. Relapsed or relapsed/refractory disease 3. Age ≥ 18 years 4. ECOG performance status (0-2) 5. Life expectancy \> 3 months 6. Adequate bone marrow and renal functions 7. QTcF \<500 msec 8. Ability to comply with treatment, PK and test schedules...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | - | Undisclosed |
STRO-001 is an investigational antibody drug conjugate being studied for the treatment of advanced B-cell malignancies, including B-cell lymphoma, non-Hodgkin lymphoma, multiple myeloma, follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, and indolent lymphoma. It is currently in clinical development and has not been approved by the FDA.
STRO-001 targets CD74, a protein expressed on B cells. As an antibody drug conjugate, it is designed to deliver a cytotoxic agent to CD74-expressing cells. This mechanism is being evaluated in patients with advanced B-cell malignancies, including B-cell lymphoma and multiple myeloma.
STRO-001 is being developed by Sutro Biopharma, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol STRO. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced B-cell malignancies.
STRO-001 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 study of STRO-001 in patients with advanced B-cell malignancies has been completed, with results expected to inform further development.
STRO-001 has been studied in a Phase 1 clinical trial with the identifier NCT03424603. This completed study enrolled 70 participants with advanced B-cell malignancies, including B-cell lymphoma and multiple myeloma, at sites in the United States. The trial was uncontrolled and not randomized or double-blinded.
Yes, STRO-001 is an anti-CD74 antibody drug conjugate. It is designed to target CD74, a protein found on B cells, and deliver a cytotoxic payload. This investigational drug is being developed by Sutro Biopharma for the treatment of advanced B-cell malignancies.